Ascletis Pharma (ASCLF) News Today $0.18 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Ascletis Pharma Inc.: Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of AcneNovember 12, 2024 | finanznachrichten.deAscletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of ObesityNovember 7, 2024 | prnewswire.comAscletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of ObesitySeptember 17, 2024 | prnewswire.comChina Shineway Pharmaceutical Group Ltd 02877July 26, 2024 | morningstar.comModerate to Severe Acne Pipeline Landscape Analysis, 2024, Featuring Emerging Therapies ASC40 (Ascletis Pharma), BTX 1503 (Botanix Pharmaceuticals), and MoreJune 6, 2024 | globenewswire.comAscletis Announces Strategic Decisions on FXR agonist ASC42April 3, 2024 | prnewswire.comAscletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual MeetingMarch 10, 2024 | prnewswire.comWeek In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From ChinaJanuary 28, 2024 | seekingalpha.comAscletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of AcneJanuary 24, 2024 | finance.yahoo.comGannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASHJanuary 23, 2024 | finance.yahoo.comGannex Announces Positive Interim Results from 52-Week Phase II Clinical Trial of Once-Daily ASC41 Tablet in Patients with Biopsy-Confirmed Non-alcoholic SteatohepatitisJanuary 2, 2024 | finance.yahoo.comAscletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of AcneDecember 5, 2023 | finance.yahoo.comAscletis Announces Poster Presentations at AASLD Annual Meeting 2023 Including a Late-Breaking Abstract of Interim Results from Phase IIb Expansion Cohort of ASC22 for Functional Cure of CHBNovember 12, 2023 | finance.yahoo.comDr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023November 8, 2023 | finance.yahoo.comGannex Published Phase I Data of ASC42, a Novel Farnesoid X Receptor Agonist on the Journal Drugs in R&DNovember 6, 2023 | finance.yahoo.comAscletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional CureSeptember 28, 2023 | finance.yahoo.comAscletis enrols all patients in trial of glioblastoma therapySeptember 26, 2023 | msn.comAscletis Announces Completion of Enrollment of 120 Patients in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent GlioblastomaSeptember 26, 2023 | finance.yahoo.comClinical Results of ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV Infection Presented at the 12th IAS Conference on HIV ScienceJuly 24, 2023 | prnewswire.comAscletis Announces Poster Presentation of Phase II Study of ASC42 FXR Agonist for Functional Cure of Chronic Hepatitis B at EASL CONGRESS 2023June 26, 2023 | finance.yahoo.comAscletis Pharma: China Approves To Conduct Phase IIa Clinical Trial For ASC10 To Treat RSV InfectionMay 8, 2023 | markets.businessinsider.comAscletis Announces China NMPA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus InfectionMay 8, 2023 | finance.yahoo.comAscletis Announces ASC40, a First-in-Class, Once-Daily Oral FASN Inhibitor, Achieved Endpoints in Phase II Clinical Trial for AcneMay 2, 2023 | finance.yahoo.comAscletis (1672.HK) Included in the Hang Seng Hong Kong-Listed Biotech IndexFebruary 27, 2023 | finance.yahoo.comAscletis Announces U.S. FDA Approval of Conducting a Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus InfectionJanuary 31, 2023 | finance.yahoo.comAscletis Announces IND Approval of Oral Viral Polymerase Inhibitor ASC10 for Monkeypox Indication by China NMPAJanuary 26, 2023 | finance.yahoo.comSupply enters ritonavir tablets supply agreement with SimcereJanuary 17, 2023 | msn.comAscletis Announces Entering into a Supply Agreement of Ritonavir Tablets with SimcereJanuary 16, 2023 | finance.yahoo.comAscletis Announces Dosing of 4 Healthy Subjects of the First Cohort in Multiple-Dose Escalation Phase I Clinical Trial of Oral 3CLpro Inhibitor ASC11 for COVID-19January 15, 2023 | finance.yahoo.comViking Therapeutics sues Ascletis Pharma for stealing trade secretsJanuary 3, 2023 | msn.comAscletis' NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as PlannedDecember 20, 2022 | finance.yahoo.comAscletis Announces Notice of Issuance of the U.S. Patent for Oral Viral Polymerase Inhibitor ASC10 and Its DerivativesDecember 19, 2022 | finance.yahoo.comAscletis Announces Positive Early-Stage Results Of Oral RdRp Inhibitor ASC10 For COVID-19December 12, 2022 | markets.businessinsider.comAscletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19December 12, 2022 | finance.yahoo.comAscletis Pharma Shares Gain After Covid-19 Drug Approved for Clinical TrialDecember 7, 2022 | marketwatch.comAscletis Pharma Announces IND Approval For ASC11 In China - Quick FactsDecember 7, 2022 | markets.businessinsider.comAscletis gets Chinese drug regulator nod to start trial of oral COVID therapyDecember 7, 2022 | seekingalpha.comAscletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for AcneNovember 30, 2022 | finance.yahoo.comAscletis Pharma : FDA Approves IND Of Oral 3CLpro Inhibitor ASC11 For COVID-19November 23, 2022 | markets.businessinsider.comAscletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDANovember 23, 2022 | finance.yahoo.comAscletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPANovember 16, 2022 | finance.yahoo.comAscletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19November 1, 2022 | finance.yahoo.comAscletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox IndicationOctober 26, 2022 | finance.yahoo.comWeek In Review: AIM Vaccine Stages $20 Million IPO On Hong Kong ExchangeOctober 10, 2022 | seekingalpha.comAscletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts in Multiple-Dose Escalation Phase I Clinical Trial of Oral RdRp Inhibitor ASC10 for COVID-19October 10, 2022 | finance.yahoo.comAscletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASHOctober 4, 2022 | finance.yahoo.comAscletis Pharma Inc (1672)September 29, 2022 | investing.comShanghai Public Health Clinical Center Completed Patient Enrollment in Clinical Study of PD-L1 Antibody ASC22 (Envafolimab) in Combination with Chidamide for Functional Cure of HIV InfectionSeptember 15, 2022 | finance.yahoo.comAscletis Pharma : China Approves IND Of Oral RdRp Inhibitor ASC10 For COVID-19August 21, 2022 | nasdaq.comGannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary CholangitisAugust 16, 2022 | finance.yahoo.com Get Ascletis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASCLF and its competitors with MarketBeat's FREE daily newsletter. Email Address [625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen. Register for the FREE Workshop Now & get $10 in Bitcoin ASCLF Media Mentions By Week ASCLF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASCLF News Sentiment▼0.000.47▲Average Medical News Sentiment ASCLF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASCLF Articles This Week▼00▲ASCLF Articles Average Week Get Ascletis Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ASCLF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Algernon Pharmaceuticals News Today ALK-Abelló A/S News Today Alpha Tau Medical News Today Arno Therapeutics News Today Ascentage Pharma Group International News Today Avacta Group News Today Awakn Life Sciences News Today AXIM Biotechnologies News Today BerGenBio ASA News Today BriaCell Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ASCLF) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascletis Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascletis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ASCLF Stock Alerts